129 related articles for article (PubMed ID: 2550233)
1. Comparative antimicrobial activity of the new macrolides against Borrelia burgdorferi.
Preac-Mursic V; Wilske B; Schierz G; Süss E; Gross B
Eur J Clin Microbiol Infect Dis; 1989 Jul; 8(7):651-3. PubMed ID: 2550233
[TBL] [Abstract][Full Text] [Related]
2. Comparative in vitro activity of azithromycin, clarithromycin, erythromycin and lomefloxacin against Mycoplasma pneumoniae, Mycoplasma hominis and Ureaplasma urealyticum.
Renaudin H; Bébéar C
Eur J Clin Microbiol Infect Dis; 1990 Nov; 9(11):838-41. PubMed ID: 1964899
[TBL] [Abstract][Full Text] [Related]
3. Effect of pH variation on the susceptibility of Helicobacter pylori to three macrolide antimicrobial agents and temafloxacin.
Malanoski GJ; Eliopoulos GM; Ferraro MJ; Moellering RC
Eur J Clin Microbiol Infect Dis; 1993 Feb; 12(2):131-3. PubMed ID: 8388791
[TBL] [Abstract][Full Text] [Related]
4. Comparative antimycobacterial activities of difloxacin, temafloxacin, enoxacin, pefloxacin, reference fluoroquinolones, and a new macrolide, clarithromycin.
Gorzynski EA; Gutman SI; Allen W
Antimicrob Agents Chemother; 1989 Apr; 33(4):591-2. PubMed ID: 2524998
[TBL] [Abstract][Full Text] [Related]
5. In-vitro activity of ciprofloxacin, temafloxacin, azithromycin, clarithromycin and metronidazole against Giardia lamblia.
Ikerd TR; Koletar SL
J Antimicrob Chemother; 1993 Apr; 31(4):615-7. PubMed ID: 8390436
[No Abstract] [Full Text] [Related]
6. Activity of new macrolides against Bordetella pertussis and Bordetella parapertussis.
Hoppe JE; Eichhorn A
Eur J Clin Microbiol Infect Dis; 1989 Jul; 8(7):653-4. PubMed ID: 2550234
[TBL] [Abstract][Full Text] [Related]
7. In vitro susceptibilities of mycoplasmas and ureaplasmas to new macrolides and aryl-fluoroquinolones.
Waites KB; Cassell GH; Canupp KC; Fernandes PB
Antimicrob Agents Chemother; 1988 Oct; 32(10):1500-2. PubMed ID: 2973283
[TBL] [Abstract][Full Text] [Related]
8. Comparative in vitro activity of A-56268.
Sefton AM; Maskell JP; Yong FJ; Chi SJ; Williams JD
Eur J Clin Microbiol Infect Dis; 1988 Dec; 7(6):798-802. PubMed ID: 2975218
[TBL] [Abstract][Full Text] [Related]
9. Comparison of in vitro activities of ketolides, macrolides, and an azalide against the spirochete Borrelia burgdorferi.
Hunfeld KP; Wichelhaus TA; Rödel R; Acker G; Brade V; Kraiczy P
Antimicrob Agents Chemother; 2004 Jan; 48(1):344-7. PubMed ID: 14693564
[TBL] [Abstract][Full Text] [Related]
10. In-vitro activity of quinolones and macrolides against mycobacteria.
Yew WW; Piddock LJ; Li MS; Lyon D; Chan CY; Cheng AF
J Antimicrob Chemother; 1994 Sep; 34(3):343-51. PubMed ID: 7829409
[TBL] [Abstract][Full Text] [Related]
11. The in vitro activity of some 14-, 15- and 16- membered macrolides against Staphylococcus spp., Legionella spp., Mycoplasma spp. and Ureaplasma urealyticum.
Felmingham D; Robbins MJ; Sanghrajka M; Leakey A; Ridgway GL
Drugs Exp Clin Res; 1991; 17(2):91-9. PubMed ID: 1650694
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo susceptibility of the Lyme disease spirochete, Borrelia burgdorferi, to four antimicrobial agents.
Johnson RC; Kodner C; Russell M
Antimicrob Agents Chemother; 1987 Feb; 31(2):164-7. PubMed ID: 3566246
[TBL] [Abstract][Full Text] [Related]
13. [In vitro sensitivity to antibiotics of genital mycoplasmas isolated in Toulouse. Study of new molecules (macrolides and quinolones)].
Bauriaud R; Séror C; Lareng MB; Lefèvre JC
Pathol Biol (Paris); 1992 May; 40(5):479-82. PubMed ID: 1495830
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo susceptibility of Borrelia burgdorferi.
Mursic VP; Wilske B; Schierz G; Holmburger M; Süss E
Eur J Clin Microbiol; 1987 Aug; 6(4):424-6. PubMed ID: 3665899
[TBL] [Abstract][Full Text] [Related]
15. Comparative activity of quinolones, macrolides and ketolides against Legionella species using in vitro broth dilution and intracellular susceptibility testing.
Stout JE; Sens K; Mietzner S; Obman A; Yu VL
Int J Antimicrob Agents; 2005 Apr; 25(4):302-7. PubMed ID: 15784309
[TBL] [Abstract][Full Text] [Related]
16. Susceptibility of ninety-eight clinical isolates of Legionella to macrolides and quinolones using the Etest.
Schrock J; Hackman BA; Plouffe JF
Diagn Microbiol Infect Dis; 1997 Aug; 28(4):221-3. PubMed ID: 9327252
[TBL] [Abstract][Full Text] [Related]
17. Activities of sparfloxacin, azithromycin, temafloxacin, and rifapentine compared with that of clarithromycin against multiplication of Mycobacterium avium complex within human macrophages.
Perronne C; Gikas A; Truffot-Pernot C; Grosset J; Vilde JL; Pocidalo JJ
Antimicrob Agents Chemother; 1991 Jul; 35(7):1356-9. PubMed ID: 1656860
[TBL] [Abstract][Full Text] [Related]
18. Comparative in vitro activities of clarithromycin, azithromycin, and erythromycin against Borrelia burgdorferi.
Dever LL; Jorgensen JH; Barbour AG
Antimicrob Agents Chemother; 1993 Aug; 37(8):1704-6. PubMed ID: 8215288
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of lomefloxacin (SC 47111 or NY-198) against isolates of Legionella spp.
Dubois J; Joly JR
Diagn Microbiol Infect Dis; 1989; 12(3 Suppl):89S-91S. PubMed ID: 2791504
[TBL] [Abstract][Full Text] [Related]
20. Azithromycin and clarithromycin: overview and comparison with erythromycin.
Whitman MS; Tunkel AR
Infect Control Hosp Epidemiol; 1992 Jun; 13(6):357-68. PubMed ID: 1320067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
